Transcranial magnetic stimulation for tinnitus: Using the Tinnitus Functional Index to predict benefit in a randomized controlled trial

Sarah Theodoroff, Susan Griest, Robert L. Folmer

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

Background: Identifying characteristics associated with transcranial magnetic stimulation (TMS) benefit would offer insight as to why some individuals experience tinnitus relief following TMS treatment, whereas others do not. The purpose of this study was to use the Tinnitus Functional Index (TFI) and its subscales to identify specific factors associated with TMS treatment responsiveness. Methods: Individuals with bothersome tinnitus underwent 2000 pulses of 1-Hz TMS for 10 consecutive business days. The primary outcome measure was the TFI which yields a total score and eight individual subscale scores. Analyses were performed on baseline data from the active arm (n = 35) of a prospective, double-blind, randomized placebo-controlled clinical trial of TMS for tinnitus. Results: Baseline total TFI score and three of the eight TFI subscales were useful in differentiating between responders and nonresponders to TMS intervention for tinnitus. These findings are not definitive, but suggest potential factors that contribute to perceived benefit following TMS. Conclusions: Overall, the main factor associated with TMS benefit was a higher tinnitus severity score for responders at baseline. The TFI subscales helped to clarify the factors that contributed to a higher severity score at baseline. Large-scale prospective research using systematic approaches is needed to identify and describe additional factors associated with tinnitus benefit following TMS. Trial registration: ClinicalTrials.gov, ID: NCT01104207. Registered on 13 April 2010.

Original languageEnglish (US)
Article number64
JournalTrials
Volume18
Issue number1
DOIs
StatePublished - Feb 9 2017

Fingerprint

Tinnitus
Transcranial Magnetic Stimulation
Randomized Controlled Trials
Placebos
Outcome Assessment (Health Care)

Keywords

  • Questionnaire
  • Tinnitus
  • Transcranial magnetic stimulation

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Transcranial magnetic stimulation for tinnitus : Using the Tinnitus Functional Index to predict benefit in a randomized controlled trial. / Theodoroff, Sarah; Griest, Susan; Folmer, Robert L.

In: Trials, Vol. 18, No. 1, 64, 09.02.2017.

Research output: Contribution to journalComment/debate

@article{acae4109b3d747bab3a40e9ca59c371e,
title = "Transcranial magnetic stimulation for tinnitus: Using the Tinnitus Functional Index to predict benefit in a randomized controlled trial",
abstract = "Background: Identifying characteristics associated with transcranial magnetic stimulation (TMS) benefit would offer insight as to why some individuals experience tinnitus relief following TMS treatment, whereas others do not. The purpose of this study was to use the Tinnitus Functional Index (TFI) and its subscales to identify specific factors associated with TMS treatment responsiveness. Methods: Individuals with bothersome tinnitus underwent 2000 pulses of 1-Hz TMS for 10 consecutive business days. The primary outcome measure was the TFI which yields a total score and eight individual subscale scores. Analyses were performed on baseline data from the active arm (n = 35) of a prospective, double-blind, randomized placebo-controlled clinical trial of TMS for tinnitus. Results: Baseline total TFI score and three of the eight TFI subscales were useful in differentiating between responders and nonresponders to TMS intervention for tinnitus. These findings are not definitive, but suggest potential factors that contribute to perceived benefit following TMS. Conclusions: Overall, the main factor associated with TMS benefit was a higher tinnitus severity score for responders at baseline. The TFI subscales helped to clarify the factors that contributed to a higher severity score at baseline. Large-scale prospective research using systematic approaches is needed to identify and describe additional factors associated with tinnitus benefit following TMS. Trial registration: ClinicalTrials.gov, ID: NCT01104207. Registered on 13 April 2010.",
keywords = "Questionnaire, Tinnitus, Transcranial magnetic stimulation",
author = "Sarah Theodoroff and Susan Griest and Folmer, {Robert L.}",
year = "2017",
month = "2",
day = "9",
doi = "10.1186/s13063-017-1807-9",
language = "English (US)",
volume = "18",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Transcranial magnetic stimulation for tinnitus

T2 - Using the Tinnitus Functional Index to predict benefit in a randomized controlled trial

AU - Theodoroff, Sarah

AU - Griest, Susan

AU - Folmer, Robert L.

PY - 2017/2/9

Y1 - 2017/2/9

N2 - Background: Identifying characteristics associated with transcranial magnetic stimulation (TMS) benefit would offer insight as to why some individuals experience tinnitus relief following TMS treatment, whereas others do not. The purpose of this study was to use the Tinnitus Functional Index (TFI) and its subscales to identify specific factors associated with TMS treatment responsiveness. Methods: Individuals with bothersome tinnitus underwent 2000 pulses of 1-Hz TMS for 10 consecutive business days. The primary outcome measure was the TFI which yields a total score and eight individual subscale scores. Analyses were performed on baseline data from the active arm (n = 35) of a prospective, double-blind, randomized placebo-controlled clinical trial of TMS for tinnitus. Results: Baseline total TFI score and three of the eight TFI subscales were useful in differentiating between responders and nonresponders to TMS intervention for tinnitus. These findings are not definitive, but suggest potential factors that contribute to perceived benefit following TMS. Conclusions: Overall, the main factor associated with TMS benefit was a higher tinnitus severity score for responders at baseline. The TFI subscales helped to clarify the factors that contributed to a higher severity score at baseline. Large-scale prospective research using systematic approaches is needed to identify and describe additional factors associated with tinnitus benefit following TMS. Trial registration: ClinicalTrials.gov, ID: NCT01104207. Registered on 13 April 2010.

AB - Background: Identifying characteristics associated with transcranial magnetic stimulation (TMS) benefit would offer insight as to why some individuals experience tinnitus relief following TMS treatment, whereas others do not. The purpose of this study was to use the Tinnitus Functional Index (TFI) and its subscales to identify specific factors associated with TMS treatment responsiveness. Methods: Individuals with bothersome tinnitus underwent 2000 pulses of 1-Hz TMS for 10 consecutive business days. The primary outcome measure was the TFI which yields a total score and eight individual subscale scores. Analyses were performed on baseline data from the active arm (n = 35) of a prospective, double-blind, randomized placebo-controlled clinical trial of TMS for tinnitus. Results: Baseline total TFI score and three of the eight TFI subscales were useful in differentiating between responders and nonresponders to TMS intervention for tinnitus. These findings are not definitive, but suggest potential factors that contribute to perceived benefit following TMS. Conclusions: Overall, the main factor associated with TMS benefit was a higher tinnitus severity score for responders at baseline. The TFI subscales helped to clarify the factors that contributed to a higher severity score at baseline. Large-scale prospective research using systematic approaches is needed to identify and describe additional factors associated with tinnitus benefit following TMS. Trial registration: ClinicalTrials.gov, ID: NCT01104207. Registered on 13 April 2010.

KW - Questionnaire

KW - Tinnitus

KW - Transcranial magnetic stimulation

UR - http://www.scopus.com/inward/record.url?scp=85012106592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012106592&partnerID=8YFLogxK

U2 - 10.1186/s13063-017-1807-9

DO - 10.1186/s13063-017-1807-9

M3 - Comment/debate

C2 - 28183355

AN - SCOPUS:85012106592

VL - 18

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 64

ER -